MONTPELLIER, FRANCE – Sensorion, a pioneering clinical-stage biotechnology company dedicated to developing novel therapies for hearing loss disorders, announced significant progress in its gene therapy programs, highlighted by updated six-month efficacy data from Cohort 2 of its Phase 1/2 Audiogene trial evaluating SENS-501. Concurrently, the company provided a comprehensive development update on its GJB2 gene therapy program, GJB2-GT (SENS-601), underscoring its commitment to addressing critical unmet medical needs in genetic hearing loss. These updates mark a crucial juncture for Sensorion, reinforcing the potential of gene therapy to transform the lives of individuals affected by profound deafness.
Sustained Efficacy and Favorable Safety Profile in Audiogene Trial
The primary focus of Sensorion’s latest announcement revolved around the Audiogene trial, which investigates SENS-501 (OTOF-GT), an innovative gene therapy designed to treat congenital deafness caused by mutations in the OTOF (otoferlin) gene. The six-month follow-up data from Cohort 2 demonstrated sustained early efficacy signals in two of the three patients who received the higher dose of SENS-501. These positive findings are consistent with the improvements initially reported at the three-month mark, providing further evidence of SENS-501’s therapeutic potential. Crucially, the observed results also align with a discernible dose-response relationship identified across the first two cohorts of the study, suggesting a predictable and potentially scalable therapeutic effect.
The Audiogene trial targets a particularly vulnerable and critical patient population: infants and toddlers aged 6 to 31 months at the time of gene therapy treatment. This age window is strategically chosen due to the optimal brain plasticity during early childhood, which maximizes the chances for young children with pre-linguistic hearing loss to acquire normal speech and language development if their hearing is restored. The trial’s design, comprising two cohorts of escalating doses followed by an expansion cohort, emphasizes a meticulous approach to both safety and efficacy evaluation. While safety remains the primary endpoint for the initial dose-escalation phase, auditory brainstem response (ABR) is designated as the primary efficacy endpoint for the subsequent expansion phase.
Beyond efficacy, the safety profile of SENS-501 has been exemplary. Across all six patients treated in the dose-escalation phase of the trial, the surgical procedure for intra-cochlear administration of SENS-501 continued to be well tolerated. Sensorion reported no serious adverse events or serious side effects, a critical milestone for any gene therapy in its early clinical development. This robust safety data, coupled with the reproducible nature of the surgical procedure and the specialized injection system developed by Sensorion, significantly bolsters confidence in the therapeutic platform. The ability to consistently deliver the gene therapy safely and effectively across different patients and dose levels is a testament to the rigorous development process and the expertise of the clinical teams involved.
Future Directions for SENS-501 and Broader Implications
Building on the promising dose-response signal observed to date, Sensorion is now actively considering the introduction of a third dose level within the existing Audiogene trial framework. This strategic decision underscores the company’s commitment to optimizing the therapeutic regimen and maximizing patient benefit. Such an expansion would necessitate consultation with regulatory authorities, a process Sensorion plans to undertake while simultaneously monitoring the broader regulatory and competitive landscape for emerging hearing loss gene therapies. The continuous evolution of this field demands agility and strategic foresight, and Sensorion appears well-positioned to navigate these complexities.
Pr. Natalie Loundon, the Principal Investigator of the Audiogene trial, articulated the profound significance of these findings. "The Audiogene trial continues to generate consistent and informative data in a very young patient population," she stated. "The sustained hearing signals observed at six months in children born with profound deafness, combined with the favorable safety profile and the reproducibility of the surgical procedure with our injection system across patients and dose levels, reinforce our confidence in the potential of gene therapy for genetic hearing loss. These results provide hope for families affected by otoferlin-mediated deafness, and the clinical expertise built through Audiogene will directly benefit patients with other monogenic forms of hearing loss who may benefit from similar gene therapy approaches in the future." Her statement not only highlights the immediate impact on OTOF-mediated deafness but also envisions a broader application of the accumulated knowledge and techniques to other forms of genetic hearing impairment, paving the way for future innovations.
Advancing the GJB2 Gene Therapy Program (SENS-601)
The insights and experience garnered through the Audiogene program are not confined to SENS-501 alone; they are proving instrumental in supporting Sensorion’s broader gene therapy platform, including the accelerated development of SENS-601 (GJB2-GT). This program targets hearing loss linked to mutations in the GJB2 gene, which represents the most common cause of genetic congenital deafness. GJB2 mutations are responsible for approximately 50% of autosomal recessive non-syndromic hearing loss, affecting a substantial global patient population. The GJB2 gene plays a critical role in maintaining the ionic balance necessary for sound transduction within the delicate structures of the inner ear. When this gene is defective, the intricate process of converting sound waves into electrical signals is disrupted, leading to profound hearing impairment.
Sensorion’s GJB2-GT program, developed in collaboration with the Institut Pasteur, is particularly ambitious due to its potential to address a wide spectrum of GJB2-related hearing loss pathologies. Beyond pediatric congenital deafness, recent research has illuminated that GJB2 mutations are also found in early-onset forms of severe presbycusis in adults. This suggests that GJB2-GT could potentially treat progressive forms of hearing loss in children and even tackle early-onset presbycusis in adults, significantly expanding its therapeutic reach. With no approved gene therapy currently available for GJB2-related hearing loss, SENS-601 holds the promise of being the first-in-human gene therapy to specifically address these prevalent mutations.
The development timeline for SENS-601 is progressing at an encouraging pace. CTA (Clinical Trial Application)-enabling studies are well underway, with Sensorion projecting CTA submission for the first half of 2026. This will be followed by an Investigational New Drug (IND) submission, targeted by the end of 2026, marking a critical step toward initiating human clinical trials in the United States. Further underscoring its commitment to scientific transparency and collaboration, Sensorion plans to present comprehensive preclinical safety, biodistribution, and efficacy data for SENS-601 at the prestigious American Society of Gene & Cell Therapy (ASGCT) annual meeting in May 2026 in Boston. This presentation will offer a detailed look into the scientific foundation supporting the GJB2-GT program, allowing the broader scientific community to review and validate its potential.
Strategic Vision and Financial Fortification
Amit Munshi, Chairman and Interim Chief Executive Officer of Sensorion, reiterated the overarching strategic importance of the Audiogene data. "The data generated through Audiogene validates the key components of our gene therapy platform, from surgical delivery, and safety through dose escalation to the observation of a dose-response relationship," he commented. This validation is not merely theoretical; it provides a robust practical framework for the advancement of Sensorion’s entire gene therapy pipeline.
Munshi further emphasized the broader ecosystem supporting Sensorion’s progress. "This growing body of clinical and procedural experience, together with the relationships we have built with leading clinical centers, regulatory agencies, and our partners, provides further confidence in the advancement of SENS-601, our potential first-in-human gene therapy program targeting GJB2-related hearing loss." He also highlighted a crucial financial development: "Our strengthened financial position following the recent financing, anchored by Sanofi’s strategic investment, positions the Company well to execute on this next phase of growth." Sanofi’s strategic investment, reported earlier, underscores the significant confidence placed in Sensorion’s innovative approach and its potential to deliver transformative treatments. This financial stability is paramount for a clinical-stage biotech company undertaking such complex and long-term development programs. Munshi concluded by reaffirming the company’s core mission: "Ultimately, our goal is to bring meaningful therapeutic options to the families and patients who today have no targeted treatment for genetic hearing loss, and we remain fully committed to this mission."
Collaborative Innovation and Foundational Research
Sensorion’s gene therapy endeavors are deeply rooted in collaborative innovation. The SENS-501 program, specifically, has been meticulously developed within the framework of the RHU AUDINNOVE consortium. This powerful alliance brings together Sensorion with esteemed institutions such as Necker Enfants Malades Hospital, the Institut Pasteur, and the Fondation pour l’Audition. This multi-institutional collaboration ensures a comprehensive approach, integrating cutting-edge research with clinical expertise and patient advocacy. The project also benefits from partial financing by the French National Research Agency through its "investing for the future" program (ref: ANR-18-RHUS-0007), signifying national recognition of its strategic importance and scientific merit.
The scientific heritage behind SENS-501 is equally profound. The OTOF gene, which is the target of the Audiogene trial, was initially discovered in 1999 at the Institut Pasteur by Prof. Christine Petit’s renowned team (Institut reConnect, Institut de l’Audition, Pasteur Institute). Her team also played a pivotal role in unraveling the pathophysiology of the corresponding deafness, known as DFNB9. This foundational research by the Institut Pasteur laid the groundwork for understanding otoferlin-mediated deafness, making their continued collaboration with Sensorion on both SENS-501 and GJB2-GT programs a powerful synergy between fundamental science and translational medicine.
Sensorion’s Broader Portfolio and Market Impact
As a clinical-stage biotech company, Sensorion has established a unique R&D technology platform designed to deepen the understanding of inner ear disease pathophysiology and etiology. This platform enables the precise selection of optimal targets and mechanisms of action for its drug candidates. While gene therapies for hereditary monogenic forms of deafness are a significant pillar of its strategy, Sensorion also maintains a diverse portfolio.
This includes clinical-stage small molecule programs, notably SENS-401 (Arazasetron), aimed at treating and preventing various hearing loss disorders. SENS-401 has progressed through three Phase 2 proof-of-concept clinical studies. The first, for Cisplatin-Induced Ototoxicity (CIO) to preserve residual hearing, concluded in Q1 2026. A second study, in partnership with Cochlear Limited, focused on residual hearing preservation in patients undergoing cochlear implantation, completed in 2024. Furthermore, a Phase 2 study of SENS-401 for Sudden Sensorineural Hearing Loss (SSNHL) was completed in 2022. These multiple programs underscore Sensorion’s broad commitment to addressing the significant global unmet medical need in hearing health, utilizing both gene therapy and small molecule approaches.
The advancements reported by Sensorion are more than just scientific milestones; they represent tangible hope for millions of individuals and families affected by genetic hearing loss. With an estimated 430 million people worldwide living with disabling hearing loss, and a significant portion attributable to genetic causes, the development of targeted, restorative therapies like SENS-501 and SENS-601 could dramatically alter the landscape of hearing healthcare. The meticulous clinical progression, robust safety data, and strategic financial positioning of Sensorion signal a promising future for gene therapy in the challenging and often underserved field of otology.